C3a and C5a Anaphylatoxins: Complement-Derived Peptides in GPCR Signaling and Inflammation Research

# C3a and C5a Anaphylatoxins: Complement-Derived Peptides in GPCR Signaling and Inflammation Research

Introduction

Every time the complement system fires, it leaves behind a pair of small, short-lived peptide fragments that punch far above their weight: C3a and C5a, the complement anaphylatoxins. Cleaved from the much larger complement proteins C3 and C5, these 74–77 amino acid peptides are among the most potent chemoattractants and pro-inflammatory signaling molecules known, acting through a small family of G-protein-coupled receptors (GPCRs) — C3aR, C5aR1, and C5aR2 — to shape everything from neutrophil recruitment to synaptic pruning.

Despite sitting at the center of innate immunity for over half a century, C3a and C5a remain a genuine research frontier with significant recent advances (PMID: 42418494, 42217620, 42034937): recent cryo-EM structures of the anaphylatoxin receptors, a first-in-class oral C5aR1 inhibitor now used in clinical vasculitis research, and an expanding literature on C3a/C5a signaling in neuroinflammation and cancer have all emerged within the last few years. This guide is a laboratory-oriented research profile of the anaphylatoxin peptides — their structure, generation, receptor pharmacology, and the tool compounds used to probe their biology.

This article is intended for laboratory research and educational purposes only. C3a, C5a, and the peptide/small-molecule tools discussed here (EP54, EP67, PMX53, avacopan) are Research Use Only (RUO) reagents and are not intended for human or animal administration, diagnosis, treatment, or prevention of any disease.

What Are Complement Anaphylatoxins?

"Anaphylatoxin" is a functional term dating to early 20th-century immunology, describing peptide fragments capable of triggering anaphylaxis-like smooth muscle contraction and mast cell degranulation when injected experimentally. Three anaphylatoxins are generated during complement activation — C3a, C4a, and C5a — but C3a and C5a are by far the most extensively studied, since C4a shows markedly weaker receptor engagement and is often considered only a partial or non-functional anaphylatoxin at physiological concentrations (Klos et al., 2013, Pharmacological Reviews).

Structurally, C3a and C5a are compact four-helix bundle peptides stabilized by three conserved intramolecular disulfide bonds, a fold shared with C4a and reflecting their common evolutionary origin from a single ancestral gene. Human C5a is 74 residues; human C3a is 77 residues. Despite this structural similarity, C5a is roughly 10- to 100-fold more potent than C3a as an inflammatory mediator in most functional assays, a difference attributable largely to how efficiently each peptide engages its receptors.

Generation: The Complement Cascade as an Anaphylatoxin Factory

C3a and C5a are not synthesized as free peptides — they are proteolytic byproducts of complement activation, generated only when the cascade fires:

1. Complement activation (via the classical, lectin, or alternative pathway) converges on formation of C3 convertases (C4b2a or C3bBb).

2. C3 convertase cleaves complement component C3 into C3a (the anaphylatoxin) and C3b (which opsonizes targets and feeds into C5 convertase assembly).

3. C5 convertases (C4b2a3b or C3bBb3b) then cleave C5 into C5a and C5b, with C5b nucleating assembly of the membrane attack complex (MAC, C5b-9).

Because C5a generation is downstream of and depends on C3a generation, the two peptides are released together during complement activation but are not functionally redundant — C3a shapes an earlier, broader stage of the response, while C5a marks a later, terminal-pathway checkpoint tightly coupled to MAC formation. Once released, both peptides are rapidly inactivated in plasma by carboxypeptidase N/B, which removes the C-terminal arginine to generate the far less active "desArg" forms (C3a-desArg, C5a-desArg) — a built-in kill switch that keeps anaphylatoxin signaling local and transient.

Receptor Pharmacology: C3aR, C5aR1, and C5aR2

C3a and C5a signal through three class A GPCRs, all expressed on myeloid cells and, increasingly recognized, on neurons, astrocytes, and epithelial cells:

• •C3aR — the sole receptor for C3a. Couples primarily to Gαi, driving chemotaxis, degranulation, and modulation of cytokine release.
• •C5aR1 (CD88) — the classical, high-affinity C5a receptor. Also Gαi-coupled, and considered the principal driver of C5a's pro-inflammatory, chemotactic, and phagocyte-activating effects.
• •C5aR2 (C5L2/GPR77) — a non-canonical, largely G-protein-independent receptor for C5a (and C3a-desArg) that signals mainly through β-arrestin recruitment. Its role is still debated: in different contexts it appears to act as a decoy/scavenger receptor that dampens C5aR1 signaling, or as an active signaling partner in its own right.

Structural biology has moved quickly on this receptor family: cryo-EM structures of C3aR–Gi and C5aR1–Gi complexes bound to their native peptide agonists have revealed how the anaphylatoxins' C-terminal residues insert into the receptor's transmembrane pocket while the folded helical core docks against the extracellular loops (revealed in the 2023 Nature Chemical Biology structural study). Crystal structures of C5aR1 in ternary complex with the peptide antagonist PMX53 and the non-peptide antagonist avacopan further show that these two drug classes occupy distinct — orthosteric versus allosteric — binding sites on the same receptor, explaining their different pharmacological profiles.

Notably, several widely used synthetic C5a peptide agonists (EP54, EP67) show meaningful cross-reactivity across C5aR1 and C5aR2, a receptor promiscuity that researchers must account for when interpreting knockout or antagonist experiments (Li, Clark & Woodruff, 2021, International Immunopharmacology).

Downstream Signaling and Cellular Effects

Engagement of C3aR or C5aR1 by their cognate ligands triggers the canonical Gαi cascade: inhibition of adenylate cyclase, activation of phospholipase Cβ, generation of IP3/DAG, intracellular calcium flux, and downstream PI3K/Akt and MAPK (ERK1/2, p38) activation. These signals converge on the following cellular effects (PMID: 37852260):

• •Chemotaxis — directed migration of neutrophils, monocytes, and mast cells toward sites of complement activation, with C5a acting as one of the most potent chemoattractants known for neutrophils.
• •Degranulation — release of granule contents from neutrophils, mast cells, and basophils, contributing to the classic anaphylatoxin-triggered vascular permeability and smooth muscle contraction.
• •Respiratory burst priming — enhanced oxidative burst capacity in phagocytes upon subsequent stimulus.
• •Cytokine and chemokine induction — upregulation of TNF-α, IL-6, and IL-1β in monocytes/macrophages, linking anaphylatoxin signaling to the broader cytokine network (see our IL-6 and TNF-α research profiles for downstream pathway detail).
• •Adaptive immune modulation — C3a and C5a also act on endothelial cells to promote B-cell activation and T-cell polarization, extending anaphylatoxin signaling beyond innate immunity into adaptive immune regulation (2024 PMC study).

C3a/C5a in Disease Models: A Widening Research Footprint

While anaphylatoxin biology was long framed narrowly around acute inflammation and anaphylaxis, contemporary research has substantially expanded the C3a/C5a footprint:

Sepsis and systemic inflammation. Excessive complement activation during sepsis generates supraphysiological C5a levels, which paradoxically impair neutrophil function ("C5a paralysis") while driving systemic vascular leak — a paradox that has made the C5a/C5aR1 axis a long-standing sepsis research target.

Neuroinflammation and CNS injury. C3a/C3aR signaling has emerged as a key modulator of microglial and astrocytic responses following ischemic stroke, with context-dependent effects that can be either deleterious (amplifying neuroinflammation and neuronal loss in the acute phase) or protective (supporting tissue remodeling in recovery) — underscoring that anaphylatoxin signaling is not simply "pro-inflammatory" but highly context- and timing-dependent. C3a signaling has also been implicated in synaptic elimination, connecting complement biology to neurodevelopmental and neurodegenerative research (a theme that resonates with our coverage of amyloid-beta and alpha-synuclein proteinopathy research, where complement-mediated synaptic pruning is an active area of investigation).

Autoimmune and vasculitic disease models. C5aR1 activation by neutrophils is now understood as a central amplification step in ANCA-associated vasculitis, where autoantibody-primed neutrophils are further activated through C5aR1 to drive vascular injury — the mechanistic basis for the receptor's status as a drug discovery target (see below).

Oncology. A growing systematic-review literature has examined C3a/C5a signaling within the tumor microenvironment, including in lymphoma, where anaphylatoxin receptor engagement on immune and stromal cells appears to shape tumor-immune crosstalk.

Infection biology. C3aR, C5aR1, and C5aR2 play distinct, sometimes opposing roles in experimental models of meningococcal infection, illustrating that the three-receptor anaphylatoxin system cannot be treated as functionally redundant even though all three respond to overlapping ligands.

Peptide and Small-Molecule Tools for Anaphylatoxin Research

The anaphylatoxin receptors have attracted an unusually rich toolkit of both peptide and non-peptide ligands, making this a well-instrumented system for receptor pharmacology research:

PMX53 remains the most widely cited peptide antagonist tool compound for C5aR1 research: it is a cyclic hexapeptide that acts as a potent, pseudo-irreversible, noncompetitive inhibitor at nanomolar concentrations, and its co-crystallization with C5aR1 provided one of the first high-resolution views of orthosteric antagonism at this receptor. Avacopan, in contrast, binds an allosteric pocket and was the first orally administered C5aR1 inhibitor to reach regulatory approval as a treatment for ANCA-associated vasculitis, making it a widely used reference compound in complement pharmacology research ([Jayne et al., ADVOCATE trial, 2021, NEJM]()). Research-integrity note: NEJM retracted this trial report in June 2026 after re-adjudication irregularities were disclosed as part of an FDA investigation; the FDA and EMA subsequently moved to withdraw/revoke avacopan's marketing authorization. The compound remains cited here only as a structural/pharmacological reference tool, not as evidence of clinical efficacy.

On the agonist side, researchers have also engineered chimeric ligands by grafting the C-terminal residues of C5a onto scaffolds recognized by C3aR, producing hybrid peptides that probe the shared and divergent recognition determinants of the two receptors (Halai et al., 2014, European Journal of Pharmacology).

Structural Research: From NMR to Cryo-EM

C5a was among the earlier GPCR peptide ligands to have its solution structure solved by NMR, revealing the conserved four-helix bundle architecture with a flexible, functionally critical C-terminal tail. More recent X-ray crystallography of human and murine C5a variants has shown that helix-bundle packing can vary subtly between species — human C5a-desArg forms a three-helix arrangement while murine C5a retains the canonical four-helix fold — a structural nuance relevant to interpreting cross-species research data (Schatz-Jakobsen et al., 2014, Acta Crystallographica D).

The field's biggest recent leap has been cryo-EM: near-simultaneous structures of agonist-bound C3aR-Gi and C5aR1-Gi complexes have finally shown, at near-atomic resolution, how the anaphylatoxin's C-terminal arginine — the residue removed by carboxypeptidase inactivation — inserts deep into the receptor's orthosteric pocket, explaining both the mechanism of receptor activation and why desArg forms lose most of their potency (PMID: 37852260).

Assay Approaches for Anaphylatoxin Research

Laboratory investigation of C3a/C5a biology typically draws on several complementary methods, many of which overlap with techniques covered elsewhere on this site:

• •Chemotaxis assays (Boyden chamber / transwell) to quantify neutrophil or monocyte migration toward C3a/C5a gradients.
• •Calcium flux assays in receptor-transfected cell lines to characterize agonist potency and antagonist blockade.
• •Radioligand and fluorescence-based binding assays to determine receptor affinity of new peptide or small-molecule ligands — conceptually related to the binding-kinetics approaches described in our surface plasmon resonance and biolayer interferometry analytical method guides.
• •Flow cytometry for receptor expression profiling and functional readouts such as CD11b upregulation on activated neutrophils, using approaches similar to those in our flow cytometry for peptide research guide.
• •ELISA-based quantification of C3a-desArg and C5a-desArg in plasma or culture supernatant as markers of complement activation, since the native peptides are too short-lived to measure directly.
• •Cryo-EM and X-ray crystallography of ligand-receptor complexes to define binding pose and inform structure-based ligand design.

Why C3a/C5a Research Matters Beyond Classical Immunology

Complement anaphylatoxin research sits at an unusually productive intersection of structural biology, GPCR pharmacology, and disease biology. The recent resolution of C3aR and C5aR1 cryo-EM structures has turned a receptor family that was pharmacologically intractable for decades into a tractable structure-based drug design target. At the same time, the expansion of C3a/C5a research into neuroinflammation, oncology, and infection biology — well beyond the classical acute-inflammation framing — illustrates a broader pattern seen across complement research: peptide fragments generated for one purpose (opsonization, terminal pathway lysis) turn out to have receptor-mediated signaling roles that ripple across nearly every organ system studied.

For labs working on cytokine and inflammatory signaling more broadly, the anaphylatoxin receptors provide a useful comparison point against classical cytokine receptor systems such as IL-1β/NLRP3 inflammasome signaling and TSLP/CRLF2 epithelial alarmin signaling — both examples of short-lived, locally acting signaling peptides whose receptor engagement drives rapid, self-limiting inflammatory programs.

Frequently Asked Questions

Are C3a and C5a the same molecule?

No. They are distinct peptides cleaved from different complement proteins (C3 and C5, respectively) at different stages of the complement cascade, with C5a generation dependent on prior C3 convertase activity. They share a common four-helix-bundle fold but differ in receptor selectivity and potency.

Why is C4a rarely discussed alongside C3a and C5a?

C4a is generated by the same general convertase mechanism but shows much weaker functional engagement with known anaphylatoxin receptors, and its physiological receptor remains poorly defined — hence its comparatively minor role in the research literature.

What is the difference between C5aR1 and C5aR2?

C5aR1 (CD88) is the canonical, G-protein-coupled signaling receptor responsible for most classical pro-inflammatory C5a effects. C5aR2 (C5L2) signals predominantly through β-arrestin rather than G-proteins and is thought to modulate — rather than replicate — C5aR1 signaling, functioning partly as a decoy/regulatory receptor.

Is avacopan a peptide?

No — avacopan is a non-peptide small molecule that binds an allosteric site on C5aR1. It is included here because it is a key reference tool compound for C5aR1 research and is often compared directly against peptide antagonists like PMX53 in structural and pharmacological studies.

What is "desArg" and why does it matter for research?

DesArg forms (C3a-desArg, C5a-desArg) are the inactivated products generated when plasma carboxypeptidase N/B removes the C-terminal arginine from C3a/C5a. Because the native peptides are cleared within minutes, desArg forms are frequently used as the practical, stable biomarker measured in plasma or supernatant assays.

---

This article is provided for laboratory research and educational purposes only. All compounds and biological pathways discussed are intended strictly for Research Use Only (RUO) applications by qualified researchers in controlled laboratory settings. Nothing in this article constitutes medical advice, and none of the peptides, receptors, or reference compounds discussed are intended for human or animal diagnostic, therapeutic, or preventive use.